Breast cancer is diagnosed during a physical exam, by self-examination of the breasts, mammography, ultrasound testing, and biopsy. A new study reveals that this scourge can be cured with an experimental treatment that triggers immune system. TUNDE OGUNTOLA writes.
Breast cancer is a malignant tumor (a collection of cancer cells) arising from the cells of the breast. Although breast cancer predominantly occurs in women, it can also affect men. This article deals with breast cancer in women. Breast cancer and its complications can affect nearly every part of the body.
There are many risk factors that increase the chance of developing breast cancer. Although we know some of these risk factors, we don’t know the cause of breast cancer or how these factors cause the development of a cancer cell.
We know that normal breast cells become cancerous because of mutations in the DNA, and although some of these are inherited, most DNA changes related to breast cells are acquired during one’s life.
Proto-oncogenes help cells grow. If these cells mutate, they can increase growth of cells without any control. Such mutations are referred to as oncogenes. Such uncontrolled cell growth can lead to cancer.
Some of the breast cancer risk factors can be modified (such as alcohol use) while others cannot be influenced (such as age). It is important to discuss these risks with a health care provider anytime new therapies are started (for example, postmenopausal hormone therapy).
Several risk factors are inconclusive (such as deodorants), while in other areas, the risk is being even more clearly defined (such as alcohol use).
The following are risk factors for breast cancer: age, family history, personal history, menstruation, breast tissue, race, having no children or the first child after age 30 increases the risk of breast cancer.
Just recently, a woman with an aggressive form of breast cancer, which defied chemotherapy and spread to other organs, was cured with an experimental treatment that triggered her immune system, researchers has said.
The woman has been cancer-free for two years, reported the US-based team, presenting their results as “a new immunotherapy approach” for the treatment of patients with a late-stage form of the disease.
Other experts not involved in the work hailed it as “exciting.” So-called “immunotherapy” has already been shown to work in some people with cancer of the lung, cervix, blood cells (leukaemia), skin (melanoma) and bladder.
But an immune breakthrough for bowel, breast and ovary cancer has remained elusive.
In the latest study, a team extracted immune cells called lymphocytes from the patient, tweaked them in the lab, then reinjected them.
The woman was 49 when she signed up for the clinical trial after several attempts at a cure through conventional treatments had failed, said the study published in the scientific journal Nature Medicine.
The cancer had spread to various parts of her body, including the liver.
A person’s immune system is designed to kill invaders, including rogue, cancerous cells. But it can fail, often because it cannot recognise cancer cells containing the patient’s own DNA.
Immunotherapy trains a patient’s own immune cells to recognise and fight cancer.
For the new study, researchers took lymphocytes from a tumour in the woman’s body and scanned them for specific types which reacted to mutant, cancerous cells.
These were reactivated or “switched on” in the lab and injected back, along with a so-called “immune checkpoint inhibitor” — another type of immunotherapy that has shown success in other types of cancer.
This resulted in a “highly personalised” anti-cancer therapy that yielded “complete tumour regression,” the researchers wrote.
In a comment also published by Nature Medicine, expert Laszlo Radvanyi from Canada’s Ontario Institute for Cancer Research said the woman’s response to the treatment was “unprecedented” for such advanced breast cancer.
This work showed “we are now at the cusp of a major revolution in finally realising the elusive goal of being able to target the plethora of mutations in cancer through immunotherapy,” he wrote.
In a reaction via the Science Media Centre in London, immunotherapy professor Alan Melcher of The Institute of Cancer Research said the trial was “fascinating and exciting”.
The work “provides a major ‘proof-of-principle step forward, in showing how the power of the immune system can be harnessed to attack even the most difficult-to-treat cancers,” he said.
Peter Johnson, an oncology professor at the Cancer Research UK Centre, said the study confirmed the immune system can recognise some cancers, and “if this can be stimulated in the right way, even cancers that have spread to different parts of the body may be treatable.”
The technique is “highly specialised and complex”, he cautioned, and may not be suitable for many patients.
All rights reserved. This material, and other digital content on this website, may not be reproduced, published, broadcast, rewritten or redistributed in whole or in part without prior express written permission from LEADERSHIP Nigeria Newspapers. Contact: [email protected]
NEWS1 hour ago
Why FEC Suspended National Carrier Project
COVER STORIES20 hours ago
NASS Adopts 4th Version Of Electoral Amendment Bill
NEWS22 hours ago
Proposed West African Science Academy Will Spur Regional Devt – Onu
NEWS21 hours ago
‘We ‘ll Not Allow Obaseki Suffer Ambode’s Political Ordeal’
FEATURES19 hours ago
2019: PDP Presidential Aspirants And The Rush For Babangida’s Endorsement
NEWS23 hours ago
Russia Blames Israel For Shooting Down Plane
ENTERTAINMENT21 hours ago
Linda Ikeji Shows-off New Born Baby
COVER STORIES20 hours ago
Dariye Picks APC Nomination Form From Prison